X

Drug Profile

BITR 2101

Alternative Names: BIR 2101; BIT-T-2101; BITR-2101

Latest Information Update: 22 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boston Immune Technologies and Therapeutics
Class Anti-infectives; Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Regulatory T-lymphocyte inhibitors; Tumour necrosis factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cancer
Preclinical Infections

Most Recent Events

21 Aug 2023 US FDA approves IND application for BITT 2101 in Non-Hodgkin’s lymphomas
21 Aug 2023 Boston Immune Technologies and Therapeutics plans a phase I trial for Non-Hodgkin’s lymphoma in the US
31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com